CN1159047C - Active components of Chinese-medicinal medicine with weight-losing and hypolipemic actions and its relative medicine - Google Patents
Active components of Chinese-medicinal medicine with weight-losing and hypolipemic actions and its relative medicine Download PDFInfo
- Publication number
- CN1159047C CN1159047C CNB021001685A CN02100168A CN1159047C CN 1159047 C CN1159047 C CN 1159047C CN B021001685 A CNB021001685 A CN B021001685A CN 02100168 A CN02100168 A CN 02100168A CN 1159047 C CN1159047 C CN 1159047C
- Authority
- CN
- China
- Prior art keywords
- medicine
- chinese herbal
- fat
- herbal medicine
- weight
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The present invention discloses active ingredients with the functions of weight losing and fat reduction in 40 kinds of Chinese herbal medicines, and a corresponding medicine thereof. The active ingredients comprise all ingredients and ingredient combinations, which can inhibit the activity of fatty acid synthetase, all ingredients and ingredient combinations, which can activate the activity of acyl-Co A synthetase as well as all ingredients and ingredient combinations, which can inhibit the differentiation of pre-fat cells of a mouse, a rat or a person to fatty cells. Part of or all of the combinations of the 40 kinds of Chinese herbal medicines can be prepared into the medicine for losing weight and reducing fat. The present invention can be used for developing and preparing natural medicines with the advantages of clear functional ingredient, reliable mechanism, high clinical effective rate, less toxicity and fewer side effects.
Description
Technical field:
The invention belongs to natural medicine technical field, relate in particular to the compositions that is used for Weight-reducing and lipid-lowering.
Background technology:
Obesity is a global medical problem.Existing a large amount of evidences show fat closely related with multiple disease, as hypertension, and hyperlipidemia, diabetes, cardiovascular and cerebrovascular disease, breast carcinoma, infertility, children's intelligence is low inferior.With BMI (Body Mass Index) male greater than 27.8, the women is greater than 27.3 as obesity standard, the population of being obese sum is about 7,000 ten thousand in the present 18-74 of China year population, accounts for 5.8% of population; Population of being obese sum is about 6,800 ten thousand in U.S.'s population of the same age, accounts for 20% of population.About 10,000,000,000 yuans of the consumption total value that China is used to lose weight every year and obesity-related disease is treated, the U.S. then is 1,000 hundred million dollars.China's population of being obese ratio increases rapidly at present, and it is more and more outstanding that the puppy fat problem has seemed.
The exploitation of slimming medicine is main according to two principles in the world at present: the first, and appetite-suppressing is such as sibutramine (sibutramine); The second, reduce absorption, such as Orlistat (orlistat).The two also is only two appetrol on the present Chinese market, and the former commodity Qu Mei by name can be elegant and difficult to understand bent light, latter's commodity celestial Buddhist nun's gram by name.The side effect of the two is fairly obvious, and sibutramine causes xerostomia, cardiopalmus, weak, and Orlistat causes oiliness just and fat-soluble avitaminosis.Western countries are also developing slimming medicine according to new principle always, such as, find that xanthine derivative class material can add the macro-energy expenditure by accelerating the vivo oxidation metabolism, a large amount of clinical trial proof caffeine (caffeine), ephedrine (ephedrine) uses separately or unites to use has certain fat-reducing effect, but because it can cause the side effect of tachycardias and cardiopalmus not obtain clinical permission always; Mice ob expression of gene product leptin (leptin) is found and cloned to middle nineteen nineties in last century, and prove that its rat for the genotype obesity has certain antiobesity action, but the individuality of genotype obesity only accounts for the 5-10% of obese individuals sum, and cause serious local congestion and swelling pain during this material drug administration by injection, therefore also so far for obtaining clinical permission.In sum, the main weak point of existing slimming medicine is that side effect is big and clinical effective rate is low, and to design not enough science relevant and these 2 deficiencies are all with drug target.
Chinese herbal medicine is the drug resource of Chinese unique advantage, records the example of a large amount of Chinese herbal medicine Weight-reducing and lipid-lowerings at all times in the classic of TCM.But because the Chinese herbal medicine active component is indeterminate, pharmacological mechanism is unclear to wait restriction, and traditional Chinese herbal medicine can not be gone to the world, therefore China's slimming medicine of also not having independent intellectual property right so far.Beijing in 2000 world obesity and fat-reducing conference propose to develop as early as possible the target that China has the Weight-reducing and lipid-lowering new drug of independent intellectual property right.
Summary of the invention:
The objective of the invention is to solve the existing shortcoming that the slimming medicine clinical effective rate is low, side effect is big, a kind of target spot design science is provided, thus the slimming medicine that side effect is little, clinical effective rate is high.
Technical scheme of the present invention is as follows:
In view of containing in following each single Chinese herbal medicine to fatty acid synthetase (fatty acid synthase, FAS) activity has inhibiting composition, to fatty acyl-CoA synthetase (acyl-CoA synthase, ACS) activity has the composition of activation, and mice, rat or people's preceding adipose cell (preadipocyte) is had inhibiting composition to adipose cell (adipocyte) differentiation:
Fructus Jujubae, Radix Et Rhizoma Rhei, Fructus Crataegi, oolong tea, Radix Oenotherae erythrosepalae, Stigma Maydis, Radix Glycyrrhizae, CitrusaurantiumL.Var.amara Engl., the Rhizoma Pinelliae, Radix Rehmanniae, Semen Cassiae, Radix Angelicae Sinensis, Flos Carthami, Fructus Hordei Germinatus, Pericarpium Zanthoxyli, Aloe, Radix Polygoni Multiflori, Ganoderma, Pericarpium Citri Reticulatae, Folium Ilicis, Flos Jasmini Sambac, Folium Acanthopanacis Senticosi, Rhizoma Polygoni Cuspidati, Herba Apocyni veneti, Rhizoma Alismatis, Herba Artemisiae Scopariae, Radix Rubiae, Poria, gynostemma pentaphyllum, Fructus Lycii, Fructus Gardeniae, Folium Nelumbinis, Radix Bupleuri, Radix Scutellariae, the Radix Astragali, Rhizoma Coptidis, Flos Chrysanthemi, Folium Ginkgo, Folium Sennae, Radix Puerariae
And these active component or its combination have significant fat-reducing and antihyperglycemic, and part combination or whole combination in the said herbal medicine can be mixed with Weight-lossing hypolipemic medicine.
The compositions with fat-reducing and antihyperglycemic that the present invention specifically provides is to be made by following column weight amount proportion raw material: Semen Cassiae 300, oolong tea 180, Flos Chrysanthemi 150, Pericarpium Citri Reticulatae 150, Stigma Maydis 120.
The authentication method of related activity composition is in the said herbal medicine:
One, identify whether to contain in the Chinese herbal medicine have the method for inhibiting active component to be to fatty acid synthetase:
1. separation and purification rat body fat acid enzyme:
Reach testis fat on every side around winning subcutaneous rat, kidney, merge, shred.The 0.25M sucrose solution that adds about 3 times of volumes, homogenate.Homogenate centrifugal 60 minutes in 100000 * g is got supernatant, is the FAS crude extract.In this crude extract, add solid ammonium sulfate to 25% saturation while stirring, continue to stir 10 minutes, centrifugal 10 minutes of 12000 * g discards precipitation, adds solid ammonium sulfate to 40% saturation in supernatant again, stirred 15 minutes, centrifugal collecting precipitation is dissolved in and contains 1mM DTT in right amount, 1mM EDTA, in the 4mM kaliumphosphate buffer of pH7.0, be the FAS of purification.More than operation is all carried out under 0-4 ℃.
2. the water extract or the ethanol extraction that prepare Chinese herbal medicine:
A, water extract preparation:
Each single Chinese herbal medicine is drunk sheet, prefabricated, pulverizing.Add 5 times of volume distilled water, boiled 30 minutes, 8 layers of white filtered through gauze are got clear liquid; Sediment adds 5 times of volume distilled water again, boils 30 minutes, and 8 layers of white filtered through gauze are got clear liquid.Twice clear liquid merges lyophilization.Gained dry powder is dissolved in an amount of distilled water, obtains pale brown color or brownish red transparency liquid extract, measure soluble solid content, make in each time extraction of each single Chinese herbal medicine and be stabilized in 30-100mg/ml with the evaporated under reduced pressure method.This extract is preserved down for 2-8 ℃ muddy the appearance more than 72 hours.
B, ethanol extraction preparation:
Each single Chinese herbal medicine is drunk sheet, prefabricated, pulverizing.Dehydrated alcohol refluxes 3 times, and backflow merges, and obtains pale brown color or brownish red transparency liquid extract, measures soluble solid content with the evaporated under reduced pressure method, makes in each time extraction of each single Chinese herbal medicine and is stabilized in 20-40mg/ml.
3. set up fatty acid synthetase and survey live body system, in surveying live body system, add Chinese herbal medicine extract, carry out the fatty acid synthetase activity and suppress experiment, calculate the inhibition degree, confirm whether contain the active composition of inhibition fatty acid synthetase in the Chinese herbal medicine.
Set up fatty acid synthetase and survey live body system: use spectrophotography.Surveying live body is cumulative volume 1.0ml, comprises that reaction starts thing malonyl coenzyme A 0.05ml.The enzyme amount that depends on the NADPH oxidation of malonyl coenzyme A with 37 ℃ of following per minute catalysis 1.0 μ mol is the unit of activity of FAS, and the unit of activity number that every milligram of pheron contains is the ratio vigor (u/mg) of FAS.
Carrying out active inhibition of fatty acid synthetase tests: add Chinese herbal medicine water extract or ethanol extraction in surveying live body system, make itself and enzyme effect add start material after 5 minutes.The extracts of Chinese herbal medicine addition is that every milliliter of survey live body is 5 μ l extracts of Chinese herbal medicine, is contrast with 5 μ l distilled waters or dehydrated alcohol.Calculate the inhibition degree, confirm to have inhibiting active component.
Two, identify whether to contain in the Chinese herbal medicine have the method for the active component of activation to be to fatty acyl-CoA synthetase:
1. separation and purification liver tissues of rats fatty acyl-CoA synthetase:
Win the about 200g of rat liver, chopping.The 0.25M sucrose solution that adds about 3 times of volumes, homogenate.Homogenate centrifugal 10 minutes in 600 * g, deposit seed places the 0.25M sucrose solution recentrifuge of about 3 times of volumes again, and the two times centrifugal supernatant merges.With 230000 * g centrifugal 60 minutes, get precipitation; Precipitation is suspended in (this mixed liquor contains 5mM Triton X-100,50mM pH7.4 kaliumphosphate buffer, 5mM beta-mercaptoethanol and 1mM EDTA in an amount of mixed liquor, the about 4.5mg/ml of protein concentration), left standstill 1 hour centrifugal 60 minutes of 230000 * g, get supernatant, be the ACS crude extract.The solution dilution ACS crude extract that contains 2mMTriton X-100 and 5mM beta-mercaptoethanol with about 5 times of volumes, with Blue-Sepherose chromatographic column (CL-6B on the diluent, 2.6 * 18cm) with Buffer A (the 100mM sodium phosphate that contains 10mM ATP and 0.8M NaCl of 5 times of volumes, the 25mM potassium citrate, pH7.0) wash post, with the Buffer A eluting that contains 10mM ATP and 0.8M NaCl, flow velocity 15ml/ hour, every 15ml collected at last.The part that will contain maximum enzyme activity merges, and is the ACS of purification.More than operation is all carried out under 0-4 ℃.
2. preparation Chinese herbal medicine water extract or ethanol extraction: method is with fatty acid synthetase is carried out step in the molecular level screening technique as target spot.
3. set up fatty acyl-CoA synthetase and survey live body system, in surveying live body system, add Chinese herbal medicine water extract or ethanol extraction, carry out the active activation experiment of fatty acyl-CoA synthetase, the computing activation degree confirms whether contain the active component that fatty acyl-CoA synthetase is had activation in the Chinese herbal medicine.
Set up fatty acyl-CoA synthetase and survey live body system: use isotope method.Surveying live body is cumulative volume 1.0ml, comprises that reaction starts thing coenzyme A 0.05ml.Generate 1.0 μ mol C with 35 ℃ of following per minutes
14The enzyme amount of-labelling Palmic acid coenzyme A is represented the unit of activity of ACS, and the unit of activity number that contains with every milligram of pheron is represented the ratio vigor (u/mg) of ACS.
Carry out the active activation experiment of fatty acyl-CoA synthetase: in surveying live body system, add Chinese herbal medicine water extract or ethanol extraction, make itself and enzyme effect add start material after 5 minutes.The extracts of Chinese herbal medicine addition is that every milliliter of survey live body is 5 μ l extracts of Chinese herbal medicine, is contrast with 5 μ l distilled waters or dehydrated alcohol.The computing activation degree confirms whether contain the active component that fatty acyl-CoA synthetase is had activation in the Chinese herbal medicine.
Three, identify whether to contain in the Chinese herbal medicine have the method for inhibiting active component to be to the mature fat cell differentiation to adipose cell before mice, rat or the people:
1. preparation Chinese herbal medicine water extract or ethanol extraction: method is with fatty acid synthetase is carried out step in the molecular level screening technique as target spot.
2. carry out mice, rat or the differentiation of people's adipose cell and suppress experiment, detect the repressed degree of cell differentiation, inhibiting active component is arranged thereby confirm whether to contain in the Chinese herbal medicine pair cell differentiation.Method can for:
Adipose cell before mice, rat or the people is inoculated in 96 orifice plates with certain density, cultivates with growth medium is conventional.Changing division culture medium after cell converges into, and add the extracts of Chinese herbal medicine of variable concentrations, is contrast with the distilled water or the dehydrated alcohol of equal volume, cultivated 6 days, during change liquid as required.Measure fat content in the cell with the oil red O stain method, determine differentiation degree, detect the repressed degree of cell differentiation, inhibiting active component is arranged thereby confirm whether to contain in the Chinese herbal medicine pair cell differentiation in conjunction with cellular morphology.
According to the method described above, we have carried out Preliminary Identification to the related activity composition in described 40 kinds of Chinese herbal medicine, these 40 kinds of Chinese herbal medicine extracts are to fatty acid synthetase (fatty acid synthase, FAS) active inhibitory action, to fatty acyl-CoA synthetase (acyl-CoA synthase, ACS) active activation, mice, rat or people's preceding adipose cell (preadipocyte) is seen Table 1 to the inhibitory action of adipose cell (adipocyte) differentiation, the number of "+" in the table is represented its size to the index of correlation influence.
Table 1:
| The Chinese herbal medicine title | Inhibitory action to FAS | Activation to ACS | The adipose cell differentiation suppresses | |||
| Water extract | Alcohol extract | Water extract | Alcohol extract | Water extract | Alcohol extract | |
| Fructus Jujubae | + | |||||
| Radix Et Rhizoma Rhei | ++ | ++++ | +++ | |||
| Fructus Crataegi | + | |||||
| Oolong tea | ++ | + | ++ | |||
| Radix Oenotherae erythrosepalae | + | |||||
| Stigma Maydis | +++ | |||||
| Radix Glycyrrhizae | ++ | |||||
| CitrusaurantiumL.Var.amara Engl. | + | |||||
| The Rhizoma Pinelliae | + | |||||
| Radix Rehmanniae | + | |||||
| Semen Cassiae | +++ | ++ | ||||
| Radix Angelicae Sinensis | + | |||||
| Flos Carthami | + | + | ||||
| Fructus Hordei Germinatus | + | |||||
| Pericarpium Zanthoxyli | + | + | ||||
| Aloe | ++ | + | + | |||
| Radix Polygoni Multiflori | + | |||||
| Ganoderma | + | |||||
| Pericarpium Citri Reticulatae | ++ | + | ++ | |||
| Folium Ilicis | +++ | ++ | ||||
| Flos Jasmini Sambac | + | |||||
| Radix Et Caulis Acanthopanacis Senticosi | + | |||||
| Rhizoma Polygoni Cuspidati | + | |||||
| Herba Apocyni veneti | + | + | ||||
| Rhizoma Alismatis | + | |||||
| Herba Artemisiae Scopariae | ++ | ++ | + | |||
| Radix Rubiae | + | |||||
| Poria | + | |||||
| Herb Gynostemmae Pentaphylli | ++ | + | ||||
| Fructus Lycii | + | + | ||||
| Fructus Gardeniae | + | |||||
| Folium Nelumbinis | ++ | ++ | ||||
| Radix Bupleuri | ++ | |||||
| Radix Scutellariae | + | |||||
| The Radix Astragali | + | |||||
| Rhizoma Coptidis | + | |||||
| Flos Chrysanthemi | +++ | ++ | ||||
| Folium Ginkgo | + | |||||
| Folium Sennae | + | + | ||||
| Radix Puerariae | + | |||||
Inhibition fatty acid synthetase, activation fatty acyl-CoA synthetase that contains in the above-mentioned table 1 of reference pair each Chinese herbal medicine and the prompting that suppresses the active component of adipose cell differentiation are depended on pine torch 300g, oolong tea 180g, Flos Chrysanthemi 150g, Pericarpium Citri Reticulatae 150g, Stigma Maydis 120g.Choosing is chosen, is mixed.Added the 2000ml water boil 30 minutes, with 8 layers of white filtered through gauze; Place 1500ml water to boil once more 30 minutes medicinal residues, filter.Twice filtrate merges, and lyophilization obtains about 180g dry powder.The animal effect experiment is divided into 6 groups: negative control, the contrast of high fat, positive control 1, positive control 2, low dose group, high dose group.Negative control is a normal diet, high fat contrast adds yolk powder, cholesterol, Adeps Sus domestica for normal diet, positive control 1 adds Qu Mei for high lipid food, positive control 2 adds Xuezhikang for high lipid food, low dose group is that high lipid food adds 500mg and tried thing/kg body weight/sky, and high dose group is that high lipid food adds 3000mg and tried thing/kg body weight/sky.Every single cage of rat is raised, and experimental period is 35 days.
Test item is that body weight (BWFE) after the preceding body weight (BWSE) of the experiment of every rat, the experiment, weight increase (IBW), experiment back fatty heavy (BFFE), fat body are than (PBFBW), total foodstuff consumption (TAIF), food utilization (GIBWGFI, IPBFGFI), serum levels of triglyceride (TG), T-CHOL (TC), low density lipoprotein, LDL (LDL), fatty tissue fatty acid synthetase (FAS) activity and hepatic tissue fatty acyl-CoA synthetase (ACS) activity.
The effect experiment result shows that the above-mentioned thing that tried can obviously reduce rat body weight, body fat amount, serum levels of triglyceride and T-CHOL amount, and can significantly suppress FAS and ACS activity.It loses weight and the effect of body fat weight is better than Qu Mei, and its effect that reduces TG, TC and LDL is better than Xuezhikang.The Weight-reducing and lipid-lowering experimental result of five kinds of Chinese herbal medicine extracts sees Table 2-5.
Table 2: Qu Mei and Xuezhikang be to BWFE, IBW, BFFE, PBFBW, TG, the influence of TC and LDL
Groups BWSE BWFE IBW BFFE PBFBW TG TC LDL
(g) (g) (g) (g) (％) mmol.L
-1mmol.L
-1mmol.L
-1
B
1 49.6 340.3 290.7 24.4 7.17 3.26 3.40 0.32
B
2 47.8 328.2 280.4 26.0 7.92 3.34 4.31 0.38
B
3 46.8 310.3 263.5 23.4 7.54 2.93 3.07 0.27
B
4 55.0 344.1 289.1 28.8 8.37 3.60 3.78 0.39
B
5 45.4 301.4 256.0 22.3 7.40 3.08 3.44 0.32
B
6 48.2 325.6 277.4 24.9 7.65 3.55 3.57 0.28
B
7 52.2 335.0 282.7 25.2 7.52 3.19 3.15 0.30
B
8 46.0 315.5 269.5 26.7 8.46 3.81 3.99 0.40
average 48.9 325.1 276.2 25.2 7.75 3.35 3.59 0.33
±s 3.281 14.989 12.260 2.008 0.460 0.292 0.420 0.051
C
1 54.4 279.0 224.6 21.8 7.81 2.50 3.34 0.29
C
2 46.8 290.3 243.5 23.0 7.92 2.88 3.77 0.36
C
3 56.0 291.8 235.8 20.8 7.13 3.75 3.52 0.37
C
4 50.7 258.6 207.9 17.7 6.84 3.14 2.80 0.32
C
5 45.3 255.0 209.7 18.4 7.22 3.33 3.03 0.41
C
6 46.7 260.7 214.0 17.8 6.83 3.69 3.49 0.36
C
7 48.1 244.0 195.9 17.9 7.34 2.97 3.28 0.40
C
8 45.8 248.9 203.1 18.5 7.43 2.81 3.94 0.31
average 49.2 266.0
**216.8
**19.5
**7.32
* 3.13 3.40 0.35
±s 4.062 18.537 16.461 2.075 0.402 0.435 0.371 0.043
D
1 48.6 318.8 270.2 23.1 7.25 2.66 2.33 0.22
D
2 51.9 340.7 288.6 25.0 7.34 2.43 1.64 0.24
D
3 46.5 334.9 288.4 24.2 7.23 2.28 2.52 0.17
D
4 54.3 335.6 281.3 24.6 7.33 1.98 2.40 0.25
#D
5 44.8 - - - - - - -
D
6 46.0 306.2 260.2 21.1 6.89 2.74 1.88 0.27
D
7 47.2 320.0 272.8 22.6 7.06 2.14 1.76 0.19
D
8 45.3 308.3 263.0 22.0 7.14 2.19 2.09 0.18
average 48.1 323.5 274.9 23.2
**7.18
** 2.35
** 2.09
** 0.22
**
±s 3.373 13.765 11.512 1.438 0.161 0.279 0.340 0.038
#: rat D
5Unexpected dead in experiment.
Table 3: tried thing to BWFE, IBW, BFFE, PBFBW, TG, the influence of TC and LDL
Groups BWSE BWFE IBW BFFE PBFBW TG TC LDL
(g) (g) (g) (g) (％) mmol.L
-1mmol.L
-1mmol.L
-1
B
1 49.6 340.3 290.7 24.4 7.17 3.26 3.40 0.32
B
2 47.8 328.2 280.4 26.0 7.92 3.34 4.31 0.38
B
3 46.8 310.3 263.5 23.4 7.54 2.93 3.07 0.27
B
4 55.0 344.1 289.1 28.8 8.37 3.60 3.78 0.39
B
5 45.4 301.4 256.0 22.3 7.40 3.08 3.44 0.32
B
6 48.2 325.6 277.4 24.9 7.65 3.55 3.57 0.28
B
7 52.2 335.0 282.7 25.2 7.52 3.19 3.15 0.30
B
8 46.0 315.5 269.5 26.7 8.46 3.81 3.99 0.40
average 48.9 325.1 276.2 25.2 7.75 3.35 3.59 0.33
±s 3.281 14.989 12.260 2.008 0.460 0.292 0.420 0.051
E
1 52.0 310.8 258.8 21.1 6.79 3.27 2.93 0.18
E
2 45.6 290.5 244.9 20.0 6.88 3.00 2.47 0.37
E
3 47.3 320.3 272.9 21.0 6.56 2.75 3.13 0.26
E
4 46.8 299.0 252.2 22.3 7.46 2.96 2.36 0.28
E
5 54.5 295.4 240.9 20.4 6.91 2.67 3.20 0.41
E
6 49.2 315.4 266.2 21.7 6.88 3.44 3.12 0.35
E
7 45.0 301.5 256.5 19.5 6.47 2.89 3.44 0.33
E
8 56.1 322.1 266.0 22.7 7.05 3.05 3.01 0.29
average 49.6 306.9
** 257.3
** 21.09
** 6.88
** 3.00
** 2.96
** 0.31
±s 4.183 11.897 11.019 1.110 0.303 0.255 0.368 0.072
F
1 45.8 297.0 251.2 17.8 5.99 1.35 2.05 0.24
F
2 53.0 294.5 241.5 16.7 5.67 1.68 1.89 0.26
F
3 55.2 293.0 237.8 17.3 5.90 1.61 2.11 0.19
F
4 45.8 288.4 242.6 16.9 5.85 1.48 1.73 0.28
F
5 49.3 306.8 257.5 17.6 5.74 1.84 2.18 0.39
F
6 48.1 311.2 263.1 19.2 6.17 1.26 1.69 0.22
F
7 56.5 313.9 257.4 21.5 6.85 1.82 2.33 0.34
F
8 51.1 317.9 266.8 18.0 5.66 2.01 2.75 0.38
average 50.6 302.8
** 252.2
** 18.125
**5.98
** 1.63
** 2.09
** 0.29
±s 4.071 10.979 10.704 1.565 0.391 0.258 0.345 0.075
Table 4: tried thing, Qu Mei and Xuezhikang to TAIF, the influence of GIBWGFI and IPBFGFI
Groups TAIF GIBWGFI IPBFGFI Groups TAIF GIBWGFI IPBFGFI
(g) (g) (％，×10
-3) (g) (g) (％×10
-3)
B
1 709.5 0.4097 10.1057 D
1 591.7 0.4566 12.2528
B
2 677.2 0.4141 11.6952 D
2 710.4 0.4063 10.3322
B
3 639.0 0.4124 11.7997 D
3 703.7 0.4098 10.2743
B
4 688.4 0.4200 12.1586 D
4 706.1 0.3984 10.3810
B
5 650.1 0.3938 11.3829 #D
5 - - -
B
6 633.4 0.4380 12.0777 D
6 598.5 0.4348 11.5121
B
7 700.3 0.4037 10.7383 D
7 638.4 0.4273 11.0589
B
8 632.8 0.4259 13.3692 D
8 628.6 0.4184 11.3586
average 666.3 0.415 11.666 average 653.9 0.422
* 11.024
**
±s 31.263 0.014 0.979 ±s 51.986 0.020 0.743
C
1 489.6 0.4587 15.9518 E
1 660.0 0.3921 10.2879
C
2 584.4 0.4167 13.5534 E
2 561.0 0.4365 12.2638
C
3 681.5 0.3460 10.4622 E
3 671.6 0.4063 9.7677
C
4 486.5 0.4273 14.0596 E
4 587.6 0.4292 12.6957
C
5 555.7 0.3774 12.9926 E
5 624.0 0.3861 11.0737
C
6 718.2 0.2980 9.5099 E
6 585.6 0.4546 11.7486
C
7 434.9 0.4504 16.8774 E
7 608.4 0.4216 10.6345
C
8 428.5 0.4740 17.3396 E
8 633.1 0.4202 11.1357
average 547.4
** 0.406
** 13.843
** average 616.4
** 0.418 11.201
**
±s 108.520 0.061 2.852 ±s 38.165 0.023 0.992
F
1 577.8 0.4348 10.3669
F
2 601.3 0.4016 9.4296
F
3 537.4 0.4425 10.9788
F
4 609.0 0.3984 9.6059
F
5 638.6 0.4032 8.9884
F
6 571.0 0.4608 10.8056
F
7 594.6 0.4329 11.5203
F
8 619.7 0.4305 9.1335
average 593.7
** 0.426
**10.10
4**
±s 31.447 0.022 0.943
# rat D
5Unexpected dead in experiment.
Table 5: tried thing, Qu Mei and Xuezhikang to FAS with ACS is active influences
Groups FAS specific activity (u/mg) FAS relative activity ACS specific activity (u/mg) ACS relative activity
B
2 210 413
B
4 249 1.000 390 1.000
B
6 238 382
average 232.3 395.0
C
2 222 443
C
4 207 0.907 398 1.061
C
6 203 416
average 210.7 419.0
D
2 217 500
D
4 229 0.938 472 1.224
D
6 208 478
average 218.0 483.3
E
2 190 645
E
4 156 0.758 530 1.422
E
6 182 510
average 176.0 561.7
F
2 109 1050
F
4 118 0.505 973 2.455
F
6 125 886
average 117.3 969.7
Advantage of the present invention and good effect: the present invention identifies the inhibition fatty acid synthetase that contains in some Chinese herbal medicine, the active component that activates fatty acyl-CoA synthetase and the differentiation of inhibition adipose cell first; The combination of these active component has tangible fat-reducing and antihyperglycemic; Its fat-reducing and antihyperglycemic mainly synthesizes, promotes steatolysis and the preceding adipose cell of inhibition to realize to the mature fat cell differentiation by suppressing body fat.
The present invention can be used to develop the preparation Weight-reducing and lipid-lowering natural drug that functional component is clear and definite, mechanism is reliable, clinical effective rate is high, toxic and side effects is little.
Embodiment:
With reference to the prompting that the table 1 in the summary of the invention part provides, depend on pine torch 300g, oolong tea 180g, Flos Chrysanthemi 150g, Pericarpium Citri Reticulatae 150g, Stigma Maydis 120g.Choosing is chosen, is mixed.Added the 2000ml water boil 30 minutes, with 8 layers of white filtered through gauze; Place 1500ml water to boil once more 30 minutes medicinal residues, filter.Twice filtrate merges, and lyophilization obtains about 180g dry powder.This dry powder contains and suppresses fatty acid synthetase, activates fatty acyl-CoA synthetase and suppresses the active component that adipose cell breaks up, and has fat-reducing and antihyperglycemic.
Claims (1)
1. the compositions with fat-reducing and antihyperglycemic is characterized in that it being to be made by following materials of weight proportions: Semen Cassiae 300, oolong tea 180, Flos Chrysanthemi 150, Pericarpium Citri Reticulatae 150, Stigma Maydis 120.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB021001685A CN1159047C (en) | 2002-01-18 | 2002-01-18 | Active components of Chinese-medicinal medicine with weight-losing and hypolipemic actions and its relative medicine |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB021001685A CN1159047C (en) | 2002-01-18 | 2002-01-18 | Active components of Chinese-medicinal medicine with weight-losing and hypolipemic actions and its relative medicine |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1363367A CN1363367A (en) | 2002-08-14 |
| CN1159047C true CN1159047C (en) | 2004-07-28 |
Family
ID=4739220
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB021001685A Expired - Fee Related CN1159047C (en) | 2002-01-18 | 2002-01-18 | Active components of Chinese-medicinal medicine with weight-losing and hypolipemic actions and its relative medicine |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1159047C (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100364579C (en) * | 2005-01-14 | 2008-01-30 | 中国人民解放军第四军医大学 | Oral medicine for treating hyperlipemia |
| CN102578576A (en) * | 2012-02-27 | 2012-07-18 | 苏州爱斯欧蒂生物科技有限公司 | Multi-effect weight-losing health-care product |
Families Citing this family (58)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1331503C (en) * | 2004-09-03 | 2007-08-15 | 蔡绪旺 | Health-care preparation for reducing blood-fat and raising human-body immunity |
| CN100453105C (en) * | 2004-09-17 | 2009-01-21 | 鲁南制药集团股份有限公司 | Composition with catharsis and toxin expelling, fat reducing and weight reducing function and preparing method |
| CN100336498C (en) * | 2004-12-17 | 2007-09-12 | 上海瑞珀聚合科技发展有限公司 | Fat-reducing and weight reducing toothpaste |
| CN100360155C (en) * | 2005-07-14 | 2008-01-09 | 郭志忠 | Traditional Chinese herb medicine tea with function of lowering fat and decreasing weight |
| CN100506240C (en) * | 2005-08-10 | 2009-07-01 | 上海中医药大学附属龙华医院 | Medicine for treating adiposis hepatica, and its preparation method |
| CN1320908C (en) * | 2005-09-29 | 2007-06-13 | 杨一丁 | Granular preparation with pure Chinese medicine for treating hypertension and hyperlipemia and arterial sclerosis |
| CN1907142B (en) * | 2006-07-27 | 2011-06-01 | 河南科技大学 | Process for preparing lotus leaf health care beverage |
| CN102370689B (en) * | 2007-08-07 | 2013-07-10 | 北京北大维信生物科技有限公司 | Application of extracts of Chinese herbal medicine folium sennae in preparation of weight-losing and lipid-lowering medicines or medicines with function of inhibiting lipase activity |
| CN102357142B (en) * | 2007-08-07 | 2014-03-12 | 北京北大维信生物科技有限公司 | Use of extract of Chinese herbal medicine seville orange flower in preparation of drug for losing weight and reducing blood fat or drug for inhibiting lipase activity |
| CN102389512B (en) * | 2007-08-07 | 2013-08-14 | 北京北大维信生物科技有限公司 | Application of extracts of Chinese herbal medicine aloe in preparation of weight-losing and lipid-lowering medicines or medicines with function of inhibiting lipase activity |
| CN102366433B (en) * | 2007-08-07 | 2013-07-10 | 北京北大维信生物科技有限公司 | Application of Chinese medicinal chrysanthemum extract in preparing medicaments with lipase activity-inhibiting action |
| CN101375978B (en) * | 2007-08-29 | 2012-08-22 | 北京星昊医药股份有限公司 | Medicinal composition for lowering blood fat |
| CN101530517B (en) * | 2008-03-12 | 2012-04-18 | 王文健 | Traditional Chinese compound for curing central obesity and nonalcoholic fatty liver disease and preparation method thereof |
| AU2009241274A1 (en) * | 2008-05-01 | 2009-11-05 | Afexa Life Sciences Inc. | Pharmaceutical composition comprising extracts of huanglian and Ku Ding Cha effective for lowering blood lipid levels |
| CN101361513B (en) * | 2008-08-29 | 2013-12-18 | 湖北智权知识产权咨询有限公司 | Chinese herbal medicine live bacteria tea beverage capable of preventing and treating hypertension and preparation method thereof |
| CN101411785B (en) * | 2008-11-18 | 2011-07-20 | 谢龙利 | Lotus and hawthorn tea drink for reducing blood fat |
| CN102058099B (en) * | 2009-11-13 | 2013-12-25 | 金士力佳友(天津)有限公司 | Health care food for losing weight |
| US9504725B2 (en) * | 2009-12-29 | 2016-11-29 | Korea Institute Of Oriental Medicine | Compositions and functional foods for treating and preventing obesity using polygonum cuspidatum butanol fraction and ethyl acetate fraction |
| CN102233119B (en) * | 2010-05-08 | 2013-12-04 | 弘美制药（中国）有限公司 | Traditional Chinese medicine composition for treating fatty liver and preparation method thereof |
| CN101862367B (en) * | 2010-07-05 | 2011-09-07 | 马建中 | Cassia seed soft capsule for reducing fat and losing weight and preparation method |
| CN102423381A (en) * | 2011-12-30 | 2012-04-25 | 苏州爱斯欧蒂生物科技有限公司 | Health tea with fat-reducing efficacy |
| CN102552884B (en) * | 2012-03-20 | 2013-11-06 | 南宁市品迪生物工程有限公司 | Weight loss secret recipe of Zhuang medicine |
| CN102640819B (en) * | 2012-04-23 | 2013-06-12 | 北京绿源求证科技发展有限责任公司 | Dietary health-care slimming tea granules |
| CN102697962B (en) * | 2012-06-12 | 2013-12-25 | 白华 | Lymph static defatting weight-losing paste |
| CN102805826B (en) * | 2012-08-28 | 2013-09-11 | 韩非 | Drug for reducing weight and beautifying facial appearance and preparation method thereof |
| CN102836390B (en) * | 2012-09-13 | 2014-07-02 | 王富春 | Weight-reducing medicine for external use |
| CN103505579A (en) * | 2013-01-09 | 2014-01-15 | 席安胜 | Weight reducing plaster prescription |
| CN103127324B (en) * | 2013-02-28 | 2015-01-07 | 卜乐 | Traditional Chinese medicinal compound for intervening obesity induced insulin resistance, and preparation method of bi-layer osmotic pump preparation thereof |
| CN103284080B (en) * | 2013-04-28 | 2014-06-11 | 安徽小菜一碟食品有限公司 | Lipid lowering and seasoning asparagus pea and processing method thereof |
| CN103300367B (en) * | 2013-06-08 | 2014-07-09 | 山西省肿瘤研究所 | Health care drink with lipid-decreasing function and preparation method thereof |
| CN103549052B (en) * | 2013-07-18 | 2014-11-26 | 芜湖乐锐思信息咨询有限公司 | Face beautifying and weight reduction tea and preparation method thereof |
| CN103409267A (en) * | 2013-08-08 | 2013-11-27 | 马健 | Health-care wine |
| CN104586663B (en) * | 2013-10-31 | 2017-10-17 | 广州市纳爱生物科技有限公司 | A kind of body slimming frost |
| CN103609767A (en) * | 2013-10-31 | 2014-03-05 | 安徽博格生物科技有限公司 | Tea bag having slimming and fat-reducing function |
| CN104055963B (en) * | 2013-11-28 | 2018-09-18 | 天津天狮生物发展有限公司 | A kind of fat reducing Chinese medicine composition and preparation method |
| CN103652183A (en) * | 2013-12-04 | 2014-03-26 | 青岛安信医疗器械有限公司 | Preparation method of traditional Chinese medicine slimming tea |
| CN103653143B (en) * | 2013-12-10 | 2016-03-02 | 河南职业技术学院 | The health drink its preparation method of hypotensive, reducing blood lipid |
| CN103960426B (en) * | 2014-05-21 | 2016-05-04 | 李继广 | A kind of Chinese medicinal tea for losing weight |
| CN104367865A (en) * | 2014-11-10 | 2015-02-25 | 成都果睿医药科技有限公司 | Cicada slough-containing pharmaceutical composition for lowering blood fat |
| CN104351427A (en) * | 2014-11-13 | 2015-02-18 | 常熟市海虞茶叶有限公司 | Cannabis-sativa tea with function of reducing fat |
| CN104352874A (en) * | 2014-11-26 | 2015-02-18 | 薛学明 | Medicine for treating obesity and preparation method of medicine |
| CN104814361A (en) * | 2015-05-22 | 2015-08-05 | 黄海英 | Duck feed additive |
| CN104911055A (en) * | 2015-06-05 | 2015-09-16 | 南京梦杨农业科技有限公司 | Weight losing waxberry wine and preparation method thereof |
| CN105112197A (en) * | 2015-09-01 | 2015-12-02 | 陈燕妮 | Dry red wine with slimming effect and brewing method thereof |
| CN105285727A (en) * | 2015-09-22 | 2016-02-03 | 南阳市汇博生物技术有限公司 | Full nutrient emulsion type formula food for obese people after fat loss surgery and preparation method of full nutrient emulsion type formula food |
| CN106036817A (en) * | 2016-05-10 | 2016-10-26 | 湛江广医医药科技开发有限公司 | Health-care food with effects of reducing blood sugar, reducing blood lipid and reducing weight |
| CN105998907A (en) * | 2016-07-09 | 2016-10-12 | 魏旭東 | Weight-losing traditional Chinese medicine composition |
| CN106038956A (en) * | 2016-08-10 | 2016-10-26 | 刘岩 | Weight reducing traditional Chinese medicinal composition and preparation method thereof |
| CN106265457A (en) * | 2016-10-09 | 2017-01-04 | 广东康容实业有限公司 | A kind of Weight-reducing health essence and preparation method |
| CN106511793A (en) * | 2016-10-21 | 2017-03-22 | 浙江工业大学 | Medicinal and dietary composition having effect of decreasing blood fat and application of composition |
| CN106913836A (en) * | 2017-03-26 | 2017-07-04 | 韩帮荣 | Umbilical region conditioning weight reducing health dropping liquid |
| CN107400591A (en) * | 2017-08-04 | 2017-11-28 | 三江县李红辉酒厂 | Health wine and preparation method thereof |
| CN107927781B (en) * | 2017-11-30 | 2021-01-12 | 陈洁真 | Traditional Chinese medicine weight-losing meal replacement |
| CN107980971A (en) * | 2017-12-26 | 2018-05-04 | 肇庆市高新区伟瑞生物科技有限公司 | A kind of herbal tea of degreasing weight reducing |
| TWI746917B (en) * | 2018-12-22 | 2021-11-21 | 大江生醫股份有限公司 | Use of citrus aurantium flower extract for reducing skin aging and fat content |
| KR102199536B1 (en) * | 2019-02-12 | 2021-01-07 | (주)보인바이오컨버젼스 | Composition for topical lipolysis comprising herbal extracts |
| CN113730316A (en) * | 2021-09-03 | 2021-12-03 | 围美辣妈(北京)健康咨询有限公司 | Body-beautifying conditioning herbal film powder and preparation method thereof |
| CN116747286B (en) * | 2023-08-10 | 2023-10-17 | 四川纤熹生物科技有限公司 | A Chinese medicinal composition with weight reducing effect, and its preparation method |
-
2002
- 2002-01-18 CN CNB021001685A patent/CN1159047C/en not_active Expired - Fee Related
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100364579C (en) * | 2005-01-14 | 2008-01-30 | 中国人民解放军第四军医大学 | Oral medicine for treating hyperlipemia |
| CN102578576A (en) * | 2012-02-27 | 2012-07-18 | 苏州爱斯欧蒂生物科技有限公司 | Multi-effect weight-losing health-care product |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1363367A (en) | 2002-08-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1159047C (en) | Active components of Chinese-medicinal medicine with weight-losing and hypolipemic actions and its relative medicine | |
| CN100337662C (en) | Medicinal composition for treating hyperlipemia and its preparing method | |
| CN102100805B (en) | Composition for relieving physical fatigue and enhancing immunologic function, preparation method thereof and application thereof | |
| CN1753682A (en) | The herbal-composition that is used for prostatosis | |
| CN1545382A (en) | Method for processing ginseng and the uses of extract of processed ginseng | |
| CN1824763A (en) | Fire internal organ nourishing wine and its preparation technology | |
| CN1191082C (en) | Chinese medicinal composition for treating fatty liver and its preparation method | |
| CN1220518C (en) | Chinese medicinal composition for anti-cancer and analgesia, its preparation method and its application in the preparation of product and medicine for treating cancer and analgesia | |
| CN1899536A (en) | Medicine for treating diabetes and hephrosis and its preparing method | |
| CN1256967C (en) | Health-preserving liver-protecting drug and method for making same | |
| CN101036722A (en) | Health-caring food for easing and improving climacteric Syndrome of men and the preparation thereof | |
| CN1537544A (en) | Composition of medicine for lowering fat, and its prepn. method | |
| CN1319588C (en) | Theory and medicine for treating high blood fat, fatty liver, liver fibrosis and preparation method | |
| CN1116891C (en) | Hepatitis B treating medicine | |
| CN1507352A (en) | Compound plant medicine and its application | |
| Cho et al. | Single-and repeated-dose toxicities of aloe fermentation products in rats | |
| CN1194743C (en) | Chinese medicinal composition for treating atrophic arthritis, preparing method and quality controlling method thereof | |
| CN1216614C (en) | Pharmaceutical composition for delaying chronic renal failure | |
| CN101062374A (en) | Method for preparing Chinese traditional combination capsule for treating cancer and the product thereof | |
| CN1679693A (en) | Medicine for treating hepatopathy and preparation thereof | |
| CN101062314A (en) | Medicine for curing gout and its preparing method | |
| CN1947787A (en) | Medicine for treating adiposis hepatica and its prepn. method | |
| CN1686302A (en) | Traditional Chinese medicine for treating non-alcoholic simple fatty liver and its preparation method | |
| CN116115724B (en) | Traditional Chinese medicine composition, pharmaceutical preparation, preparation method and application thereof | |
| CN1042395C (en) | Queen ant extrat oral liquid and its preparation method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C06 | Publication | ||
| PB01 | Publication | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C19 | Lapse of patent right due to non-payment of the annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |